To summarize, our study suggests an ultralow risk phenotype characterized by clinically used breast cancer markers (tumor size, tumor grade, PR status, HER2 status and Ki‐67 status) and molecular characteristics. This evidence concerns the gene ERBB2 and neoplasm.